RASIP1

Across TCGA pan-cancer cohorts, RASIP1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RASIP1 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher RASIP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RASIP1 expression acts as an unfavorable survival marker.

SCLC, LUAD, and LUSC are the cancer types where RASIP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.055	0.649	<.001	18	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	15	view →
LUSC	DFS	Median	All	0.268	0.649	.005	8	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
LGG	OS	Median	All	0.317	0.811	.011	6	view →
LIHC	DFS	Median	All	0.092	0.543	.016	6	view →
ACC	OS	Median	All	0.217	0.633	.045	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RASIP1–SCLC (OS)

Open the SCLC breakdown →